Welcome to our dedicated page for Intelligent Bio Solutions news (Ticker: INBS), a resource for investors and traders seeking the latest updates and insights on Intelligent Bio Solutions stock.
Intelligent Bio Solutions Inc (INBS) delivers innovative diagnostic solutions through its biosensor platform and fingerprint-based drug screening systems. This news hub provides investors and healthcare professionals with timely updates on the company’s advancements in non-invasive testing technologies.
Access comprehensive coverage of earnings reports, regulatory milestones, and product development progress. Stay informed about strategic partnerships and clinical validation studies that shape INBS’s position in life sciences. Our curated news collection simplifies tracking critical developments in portable drug screening and chronic disease monitoring solutions.
Discover updates on the Intelligent Fingerprinting Products segment’s commercial deployments and the evolving Biosensor Platform Technology applications. Bookmark this page for efficient monitoring of INBS’s contributions to modern healthcare diagnostics and workplace safety innovations.
Intelligent Bio Solutions Inc. (Nasdaq: INBS) has announced its collaboration with Dodman Limited, a UK manufacturer, to implement the Intelligent Fingerprinting Drug Screening System for workplace drug testing. This system offers a non-invasive alternative to traditional urine tests by analyzing fingerprint sweat samples. It enables quick on-site testing, yielding results in under ten minutes. Dodman aims to enhance its health and safety reputation by proactively introducing random drug testing across its operations.
Dodman's Health and Safety Manager, Chris Davies, emphasized the benefits of this approach, noting improved safety and differentiation in the market. Intelligent Bio Solutions recognizes the increasing importance of drug testing for employee safety and offers an innovative solution that is both efficient and accurate.